AbbVie Ready To Absorb Looming Japan HCV Price Hit
This article was originally published in PharmAsia News
As major multinationals move further into 2016, a drug re-pricing time bomb is ticking in Japan. But for US firm AbbVie, with its big-selling biologics and a recently launched hepatitis C drug, the impact of the price reduction will not be that severe, top executives say.
Register for our free email digests: